查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510440

放射治疗市场- 按放射性同位素（碘131、碘123、镓68、镥177、18F 与Y-90）、方法（标靶治疗、标靶诊断）、应用（肿瘤学、非肿瘤学）、全球预测（ 2024 - 2032）

Radiotheranostics Market - By Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90), Approach (Targeted Therapeutic, Targeted Diagnostic), Application (Oncology, Non-Oncology), Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计从2024 年到2032 年，放射治疗市场规模将以超过14.6% 的复合年增长率增长。激增。根据世界卫生组织的数据，2022 年估计将报告 2,000 万例新增癌症，导致 970 万人死亡。不断增长的老年人口更有可能患上癌症，这将进一步推动对放射治疗的需求，因为老年人需要更频繁的检查和个人化治疗。

创新影像和医用放射性药物的开发将提高诊断和治疗的准确性，从而提高医疗保健提供者和患者的采用率。尖端技术和医疗需求之间不断加强的合作也将有助于市场的成长。

放射治疗产业分为放射性同位素、方法、应用和区域。

根据方法，预计到 2032 年，标靶诊断领域的市场价值将以 14.2% 的复合年增长率成长，因为它能够为各种疾病提供个人化和精确的诊断。标靶诊断利用生物标记和分子标靶及早发现疾病，实现个人化治疗并减少不必要的手术和医疗费用。医疗保健提供者和患者对个人化诊断也越来越感兴趣，从而刺激了该细分市场的成长。

非肿瘤领域的放射治疗市场预计在 2024 年至 2032 年期间将成长 13.9%。放射治疗技术的进步提高了人们对放射治疗和管理各种非肿瘤疾病的能力的认识，包括神经系统疾病、心血管疾病和内分泌疾病。这种多功能性使放射学成为医疗保健领域的宝贵工具，推动了医疗保健提供者寻求针对各种医疗状况的准确且经济高效的诊断解决方案的需求。

2024 年至2032 年间，亚太地区放射治疗产业规模将以15.2% 的复合年增长率显着扩张。 （包括放射治疗）的需求。此外，政府促进健康可近性和健康负担能力的措施正在推动鼓励新放射治疗技术的研发投资，从而促进区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症盛行率上升
      • 放射治疗学在癌症诊断和治疗的应用越来越多
      • 核医学的成长趋势
    • 产业陷阱与挑战
      • 放射治疗学开发需要更高的成本
      • 治疗诊断剂的保存期限短
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按放射性同位素划分，2021 - 2032 年

  • 主要趋势
  • 碘131
  • 碘123
  • 镓68
  • 镥177
  • 18F 配备 Y-90
  • 其他放射性同位素

第 6 章：市场估计与预测：依方法，2021 - 2032

  • 主要趋势
  • 标靶治疗
  • 针对性诊断

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 肿瘤学
    • 甲状腺癌
    • 神经内分泌肿瘤
    • 肝细胞癌
    • 摄护腺癌
    • 其他肿瘤学应用
  • 非肿瘤学
    • 神经系统疾病
    • 关节炎
    • 其他非肿瘤学应用

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Life Healthcare Group
  • Nordic Nanovector ASA
  • Novartis AG
  • Progenics Pharmaceuticals, Inc.
  • Q BioMed Inc .
  • QSAM Biosciences, Inc.
  • RadioMedix
  • Radiopharm Theranostics Limited
  • Telix Pharmaceuticals Limited
  • Terumo Corporation
简介目录
Product Code: 8785

Radiotheranostics market size is anticipated to grow at over 14.6% CAGR from 2024 to 2032. As the incidence of cancer increases worldwide, the demand for advanced diagnostic and treatment solutions, including radiation therapy, is significantly surging. As per WHO, in 2022, an estimated 20 million new cancer were reported, resulting in 9.7 million deaths. The growing elderly population, which is more likely to develop cancer, will further drive the demand for radiotheranostics as the elderly require more frequent examinations and individualized treatments.

The development of innovative imaging and medical radiopharmaceuticals will improve the accuracy of diagnosis and treatment, increasing adoption by healthcare providers and patients. The growing collaboration between cutting-edge technologies and medical needs will also contribute to the market growth.

The radiotheranostics industry is classified into radioisotope, approach, application and region.

Based on approach, the market value from the targeted diagnostics segment is anticipated to grow at 14.2% CAGR through 2032, due to its ability to provide personalized and precise diagnosis for various diseases. Targeted diagnostics utilize biomarkers and molecular targets to detect diseases early, enabling personalized treatment and reducing unnecessary procedures and healthcare costs. Healthcare providers and patients are also increasingly interested in personalized diagnostics, spurring the segment growth.

Radiotheranostics market from the non-oncology segment is poised to witness 13.9% growth rate during 2024-2032. Advancements in radiation therapy technologies have increased awareness of the ability of radiation to treat and manage a variety of non-oncology diseases, including neurological diseases, cardiovascular diseases, and endocrine diseases. This versatility has made radiology a valuable tool in healthcare, driving demand among healthcare providers seeking accurate and cost-effective diagnostic solutions for a variety of medical conditions.

Asia Pacific radiotheranostics industry size will record notable expansion at 15.2% CAGR between 2024 and 2032. The rising prevalence of chronic diseases, along with improved healthcare infrastructure and higher incomes is driving the demand for diagnostic and treatment methods across the region, including radiotherapy. Moreover, government initiatives to promote health access and health affordability are driving R&D investments that encourage new radiotherapy technologies, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Growing use of radiotheranostics in cancer diagnosis and management
      • 3.2.1.3 Increasing trend of nuclear medicine
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Requirement of higher cost for radiotheranostics development
      • 3.2.2.2 Short shelf life of theranostic agents
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Radioisotope, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Iodine-131
  • 5.3 Iodine-123
  • 5.4 Gallium-68
  • 5.5 Lutetium-177
  • 5.6. 18F with Y-90
  • 5.7 Other radioisotopes

Chapter 6 Market Estimates and Forecast, By Approach, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Targeted therapeutic
  • 6.3 Targeted diagnostic

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oncology
    • 7.2.1 Thyroid cancer
    • 7.2.2 Neuroendocrine tumors
    • 7.2.3 Hepatocellular carcinoma
    • 7.2.4 Prostate cancer
    • 7.2.5 Other oncology applications
  • 7.3 Non-oncology
    • 7.3.1 Neurological disorders
    • 7.3.2 Arthitis
    • 7.3.3 Other non-oncology applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Mexico
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Life Healthcare Group
  • 9.2 Nordic Nanovector ASA
  • 9.3 Novartis AG
  • 9.4 Progenics Pharmaceuticals, Inc.
  • 9.5 Q BioMed Inc .
  • 9.6 QSAM Biosciences, Inc.
  • 9.7 RadioMedix
  • 9.8 Radiopharm Theranostics Limited
  • 9.9 Telix Pharmaceuticals Limited
  • 9.10 Terumo Corporation